Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients

Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients

Mohammad Taheri,1,* Ghazaleh Azimi,2,* Arezou Sayad,2 Mehrdokht Mazdeh,3 Shahram Arsang-Jang,4,5 Mir Davood Omrani,5 Soudeh Ghafori-Fard2 1Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Medical Genetics, Shahid Beheshti University of Medical...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Taheri M, Azimi G, Sayad A, Mazdeh M, Arsang-Jang S, Omrani MD, Ghafouri-Fard S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
multiple sclerosis
JAK/STAT pathway
protein inhibitors of activated STAT
PIAS
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/7256f591dc4045328cb78f74f5e279bb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7256f591dc4045328cb78f74f5e279bb
record_format dspace
spelling oai:doaj.org-article:7256f591dc4045328cb78f74f5e279bb2021-12-02T04:52:01ZExpression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients1178-7031https://doaj.org/article/7256f591dc4045328cb78f74f5e279bb2018-12-01T00:00:00Zhttps://www.dovepress.com/expression-analysis-of-protein-inhibitor-of-activated-stat-pias-genes--peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Mohammad Taheri,1,* Ghazaleh Azimi,2,* Arezou Sayad,2 Mehrdokht Mazdeh,3 Shahram Arsang-Jang,4,5 Mir Davood Omrani,5 Soudeh Ghafori-Fard2 1Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Neurophysiology Research Center, Hamadan University Medical Sciences, Hamadan, Iran; 4Clinical Research Development Center (CRDU), Qom University of Medical Sciences, Qom, Iran; 5Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran *These authors contributed equally to this work Objectives: Protein inhibitors of activated STAT (PIAS) are transcription co-regulator of the Janus kinase/signal transducer and activator of transcription signaling pathway as well as nuclear factor-κB family of transcription factors. Both of them are involved in cytokine release during inflammatory response. Patients and methods: Considering the role of cytokine imbalance in the pathogenesis of multiple sclerosis (MS), we compared blood expressions of PIAS1-4 genes in 48 interferon β (IFNβ)-treated MS patients with those of healthy subjects by means of real time PCR. Results: Although the expression levels of these genes were not significantly different between MS patients and healthy subjects, significant inverse correlations have been found between PIAS1 expression and age at disease onset. PIAS2 and PIAS3 expressions were inversely correlated with Expanded Disability Status Scale (EDSS) in patients. Moreover, PIAS3 expression was correlated with disease duration in patients and with age in controls. In addition, PIAS4 expression was inversely correlated with EDSS and age at disease onset while it was positively correlated with disease duration. Conclusion: The present study provides evidences for altered expression of PIAS genes in IFNβ-treated MS patients compared with healthy subjects. However, future studies are needed for elaboration of their exact function in this disorder. Keywords: multiple sclerosis, JAK/STAT pathway, protein inhibitors of activated STAT, PIASTaheri MAzimi GSayad AMazdeh MArsang-Jang SOmrani MDGhafouri-Fard SDove Medical Pressarticlemultiple sclerosisJAK/STAT pathwayprotein inhibitors of activated STATPIASPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 11, Pp 457-463 (2018)
institution DOAJ
collection DOAJ
language EN
topic multiple sclerosis
JAK/STAT pathway
protein inhibitors of activated STAT
PIAS
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
spellingShingle multiple sclerosis
JAK/STAT pathway
protein inhibitors of activated STAT
PIAS
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Taheri M
Azimi G
Sayad A
Mazdeh M
Arsang-Jang S
Omrani MD
Ghafouri-Fard S
Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
description Mohammad Taheri,1,* Ghazaleh Azimi,2,* Arezou Sayad,2 Mehrdokht Mazdeh,3 Shahram Arsang-Jang,4,5 Mir Davood Omrani,5 Soudeh Ghafori-Fard2 1Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Neurophysiology Research Center, Hamadan University Medical Sciences, Hamadan, Iran; 4Clinical Research Development Center (CRDU), Qom University of Medical Sciences, Qom, Iran; 5Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran *These authors contributed equally to this work Objectives: Protein inhibitors of activated STAT (PIAS) are transcription co-regulator of the Janus kinase/signal transducer and activator of transcription signaling pathway as well as nuclear factor-κB family of transcription factors. Both of them are involved in cytokine release during inflammatory response. Patients and methods: Considering the role of cytokine imbalance in the pathogenesis of multiple sclerosis (MS), we compared blood expressions of PIAS1-4 genes in 48 interferon β (IFNβ)-treated MS patients with those of healthy subjects by means of real time PCR. Results: Although the expression levels of these genes were not significantly different between MS patients and healthy subjects, significant inverse correlations have been found between PIAS1 expression and age at disease onset. PIAS2 and PIAS3 expressions were inversely correlated with Expanded Disability Status Scale (EDSS) in patients. Moreover, PIAS3 expression was correlated with disease duration in patients and with age in controls. In addition, PIAS4 expression was inversely correlated with EDSS and age at disease onset while it was positively correlated with disease duration. Conclusion: The present study provides evidences for altered expression of PIAS genes in IFNβ-treated MS patients compared with healthy subjects. However, future studies are needed for elaboration of their exact function in this disorder. Keywords: multiple sclerosis, JAK/STAT pathway, protein inhibitors of activated STAT, PIAS
format article
author Taheri M
Azimi G
Sayad A
Mazdeh M
Arsang-Jang S
Omrani MD
Ghafouri-Fard S
author_facet Taheri M
Azimi G
Sayad A
Mazdeh M
Arsang-Jang S
Omrani MD
Ghafouri-Fard S
author_sort Taheri M
title Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
title_short Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
title_full Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
title_fullStr Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
title_full_unstemmed Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients
title_sort expression analysis of protein inhibitor of activated stat (pias) genes in ifnβ-treated multiple sclerosis patients
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/7256f591dc4045328cb78f74f5e279bb
work_keys_str_mv AT taherim expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
AT azimig expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
AT sayada expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
AT mazdehm expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
AT arsangjangs expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
AT omranimd expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
AT ghafourifards expressionanalysisofproteininhibitorofactivatedstatpiasgenesinifnbetatreatedmultiplesclerosispatients
_version_ 1718401013047623680

Ejemplares similares